retatrutide phase 2 obesity nejm 2023 jastreboff on X: "Original Article: Triple–Hormone-Receptor Agonist for — A Trial https://t.co/jNL1GNnHPT #ADA23 https://t.co/NN12Qgg2cV" / X retatrutide phase 2 trial results

Jewison, T

Mechanisms In summary, pre-clinical studies of anti-inflammatory signalling and findings from and observational studies of clinical datasets suggest GLP-1 RAs may confer dual metabolic and disease-modifying advantages in IBD, particularly in people with obesity, but evidence from prospective trials is lacking [2]

Negative control of p53 by Sir2 promotes cell survival under stress

Through this management of GLP-1 use, Excellus BCBS has realized cost savings, as indicated by the graph below: Excellus BCBS is using what appears to be the most sensible weight loss GLP-1 prior authorization criteria in the marketplace, without significantly disrupting rebates. -USI Partner What we know about the future of GLP-1 drugs In 2024, there were significant advancements with GLP-1 indications

doi: 10.1016/j.ijantimicag.2007.12.013 35 BrassingtonP